Kindstar Globalgene Technology, Inc. (KDGTF) Stock

About Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. delivers advanced, specialized diagnostic testing solutions to hospitals throughout China. These sophisticated services are designed to assist clinical specialist physicians across a range of medical fields, including hematological oncology, rare genetic conditions, obstetrics and gynecology, neurological disorders, infectious diseases, and solid tumor analysis, among others. The company's tests play a crucial role in the early identification, prevention, and precise diagnosis of complex diseases, as well as in guiding treatment selections and evaluating the efficacy of therapeutic interventions. Its extensive laboratory infrastructure encompasses facilities for flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, general pathology, clinical immunology, microbiology, and various other specialized diagnostic techniques. Founded in 2003, the company maintains its headquarters in Wuhan, China.

Kindstar Globalgene Technology, Inc. is headquartered in CN.

Kindstar Globalgene Technology, Inc. (KDGTF) stock trades at $0.68 with a market capitalization of $675.13M. The stock is valued at a price-to-earnings (P/E) ratio of -20.10, price-to-book of 0.32, price-to-sales of 0.89. Over the past 52 weeks the stock has ranged between $0.64 and $0.71, and currently trades 4.2% below its 52-week high. It pays a dividend yielding 9.50%.

On profitability, Kindstar Globalgene Technology, Inc. generates a return on equity (ROE) of -1.56%, return on capital employed of -3.12%, an operating margin of -9.54%, a net profit margin of -4.37%.

Official website: www.kindstar.com.cn